HairClone follicle banking & cell therapy
HairClone follicle banking & cell therapy is in Phase 1 for androgenetic alopecia, developed by HairClone.
A UK follicle cryobank sold today, ahead of a cell therapy that is in unregistered early testing and has no approval.
- Developed by
- HairClone
- Current phase
- Phase 1
- Mechanism
- Stem cell activation
- Indications
- Androgenetic alopecia
- Also known as
- HairClone
- Last public activity
- No trials on record
- Copy last reviewed
- September 2026
- Record confidence
- Medium
First tests in humans. Answers 'is it safe?', not 'does it work?'.
Uses stem or progenitor cells to regenerate or replace follicle tissue.
A research record, not medical advice: being listed here says nothing about whether a treatment works or whether it is right for you. Talk to a dermatologist about your own case.
Why it matters
Notable as much for its business model as its science: it sells follicle banking today, through a licensed UK tissue bank authorised in 2019, against a therapy still in development. In March 2026 the company said clinical testing of autologous follicle-cell injections had begun in Guatemala, outside any registered trial and, by its own description, without a fixed protocol, and that patients willing to pay and travel could be considered case by case. Reasonable only if the risk is accepted explicitly, and worth understanding clearly before paying.
Development history
No phase changes recorded yet.
Registered trials
Pulled automatically from ClinicalTrials.gov. Matching is by name and development code, so occasional gaps are possible — tell us if you spot one.
No trials matched to this programme in ClinicalTrials.gov.
Listing a trial is not a recommendation to join one. Eligibility, risks and costs vary enormously — discuss any trial with your own doctor first.
Sources
- HairClone — follicle banking and cell therapy programme — Company release
- HairClone, hair follicle banking — Company release
- HairClone, frequently asked questions (treatment in Guatemala, experimental status) — Company release
- HairClone begins clinical testing — Company release, March 2026
- HairClone authorized to launch world's first hair follicle banking system — Company release, August 2019
Related programmes
Other programmes in the register with the same mechanism: Stem cell activation.
- RCH-01Phase 2RepliCel Life Sciences
- Epibiotech dermal papilla cell therapyPhase 1/2Epibiotech
- ET-02Phase 1Eirion Therapeutics
- OrganTech / Tsuji follicular primordiumPreclinicalOrganTech
- TissUse Smart Hair TransplantPreclinicalTissUse
- Aderans dermal sheath cup cells (Ji Gami)DiscontinuedAderans Research Institute
Cite this page
Hair Pipeline, "HairClone follicle banking & cell therapy — development record", hairpipeline.com/pipeline/hairclone